Jazz Pharmaceuticals updates 2025 revenue outlook

Jazz Pharmaceuticals plc reported that it plans to present a corporate overview and financial update at the J.P.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc reported that it plans to present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. In this presentation, the company states that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. Jazz also outlines expectations for revenue contributions in 2025 from key products Xywav, Epidiolex and Modeyso. The related presentation slides are provided as Exhibit 99.1.

Insights

Equity research analyst

Jazz reaffirms 2025 revenue guidance and highlights key brands.

Jazz Pharmaceuticals indicates that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. This kind of reaffirmation suggests that recent business trends have not materially deviated from what management had already communicated.

The company also emphasizes revenue expectations for Xywav, Epidiolex and Modeyso, underscoring their importance within the portfolio. Details of those expectations are contained in the presentation attached as Exhibit 99.1, which is being used for the J.P. Morgan Healthcare Conference corporate overview and financial update.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jazz Pharmaceuticals (JAZZ) disclose in this 8-K filing?

Jazz Pharmaceuticals disclosed that it will present a corporate overview and financial update at the J.P. Morgan Healthcare Conference, including its expectations for 2025 revenue.

What are Jazz Pharmaceuticals’ 2025 revenue expectations mentioned in the filing?

Jazz Pharmaceuticals states that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025.

Which Jazz Pharmaceuticals products are highlighted for 2025 revenue in this filing?

The filing highlights revenue expectations for Xywav, Epidiolex and Modeyso for the year ended December 31, 2025.

What event is Jazz Pharmaceuticals participating in according to the 8-K?

Jazz Pharmaceuticals will present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco, California, on January 13, 2026.

Where can investors find the detailed Jazz Pharmaceuticals presentation mentioned in the filing?

The detailed presentation is attached to the filing as Exhibit 99.1, titled “Presentation slides by Jazz Pharmaceuticals plc on January 13, 2026.”

Is the Jazz Pharmaceuticals conference presentation deemed filed for liability purposes?

No. The company states the information in Item 2.02, including the presentation, is not deemed “filed” under Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 09:01 AM Learn about SEC filing dates

Jazz Pharmaceuticals plc false 0001232524 0001232524 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland		001-33500		98-1032470
(State or Other Jurisdiction of Incorporation)		(Commission File No.)		(IRS Employer Identification No.)

Fifth Floor, Waterloo Exchange,

Waterloo Road, Dublin 4, Ireland D04 E5W7

(Address of principal executive offices, including zip code)

011-353-1-634-7800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share		JAZZ		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 13, 2026, Jazz Pharmaceuticals plc (the “Company”) will present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco, California, which presentation includes (i) the Company’s expectations that it will meet its previously announced total revenue guidance range for the year ended December 31, 2025 and (ii) the Company’s expectations with respect to the revenue for each of Xywav, Epidiolex and Modeyso for the year ended December 31, 2025. A copy of the presentation is attached hereto as Exhibit 99.1.

The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Presentation slides by Jazz Pharmaceuticals plc on January 13, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:		/s/ Philip L. Johnson
Name:		Philip L. Johnson
Title:		Executive Vice President and Chief Financial Officer

Date: January 12, 2026